

**AMENDMENTS**

Please cancel claims 1, 3-7, 26-33 and 35-50 without prejudice or disclaimer of the subject matter set forth therein.

This listing of claims will replace all prior versions and listings of claims in the application:

**Listing of claims:**

Please add the following new claims:

1-50. (Cancelled).

51. (new) An isolated protein that is a receptor for an N-terminal fragment of plasminogen comprising kringle domains 1-4 and wherein said protein comprises a sequence having sequence homology equal to or greater than 98% to SEQ ID No: 4.

52. (new) An isolated protein that is a receptor for an N-terminal fragment of plasminogen comprising kringle domains 1-4 and wherein said protein comprises SEQ ID No: 4.

53. (new) The isolated protein according to claim 52 that has sequence homology equal to or greater than 80% to SEQ ID Nos: 2 or 3.

54. (new) The isolated protein according to claim 52 that has sequence homology equal to or greater than 95% to SEQ ID Nos: 2 or 3.

55. (new) The isolated protein according to claim 52 that has sequence homology equal to or greater than 98% to SEQ ID Nos: 2 or 3.

56. (new) The isolated protein according to claim 52 that has sequence homology equal to or greater than 99.6% to SEQ ID Nos: 2 or 3.

57. (new) The isolated protein according to claim 52, wherein said protein has angiogenic activity.

58. (new) The isolated protein according to claim 53, wherein said protein has angiogenic activity.

59. (new) The isolated protein according to claim 54, wherein said protein has angiogenic activity.

60. (new) An isolated protein that is a receptor for an N-terminal fragment of plasminogen comprising kringle domains 1-4 and wherein said protein has sequence homology equal to or greater than 98% of SEQ ID No: 2.

61. (new) The isolated protein according to claim 60 wherein said protein is SEQ ID No: 2.

62. (new) The isolated protein according to claim 60 wherein said protein is SEQ ID No: 3.

63. (new) A method for treating an angiogenesis-related disease or disorder comprising administering an effective amount of a protein of any one of claims 51-62 to a patient in need thereof.

64. (new) A method for manufacturing a composition for the treatment of an angiogenesis-related disease comprising mixing a protein according to any one of claims 51-62 with a suitable pharmaceutical carrier.

65. (new) A composition comprising a protein according to any one of claims 51-62 together with a pharmaceutically acceptable carrier.